METHODS: Medical and pharmacy claims of adults who initiated a subsequent LOT (index) after initial osimertinib discontinuation between November 2015 and September 2019 were analyzed retrospectively.
RESULTS: A total of 135 patients met the inclusion criteria. After metastatic diagnosis, 22.2% and 49.6% of patients were treated with osimertinib in the first and second line, respectively. After osimertinib discontinuation, most patients were treated with a platinum-based chemotherapy regimen (57%), of which 40.3% included immuno-oncology therapy. Reuse or continuation of EGFR TKIs was also common (24%). Overall, the median time to treatment discontinuation for the index LOT was 2.4 months. Proportions of patients with ≥ 1 inpatient or emergency department visit were 31.9% and 35.6%, respectively.
CONCLUSIONS: The duration of the LOT following osimertinib was short and associated with tolerability issues underscoring a high unmet need for new therapies to address EGFR TKI resistance.
方法:对在2015年11月至2019年9月期间首次停用奥希替尼后开始后续LOT(指数)的成年人的医疗和药学索赔进行回顾性分析。
结果:共有135例患者符合纳入标准。转移性诊断后,22.2%和49.6%的患者在一线和二线接受奥希替尼治疗,分别。奥希替尼停药后,大多数患者接受以铂类为基础的化疗方案(57%),其中40.3%包括免疫肿瘤学治疗。EGFRTKI的重复使用或继续使用也很常见(24%)。总的来说,指数LOT的中位停药时间为2.4个月.住院或急诊科就诊≥1次的患者比例分别为31.9%和35.6%,分别。
结论:奥希替尼治疗后LOT的持续时间较短,并且与耐受性问题相关,这突显了对解决EGFRTKI耐药的新疗法的高度未满足需求。